Inpatient and Outpatient Orderable

Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum Build info

Synonyms

  • ENCEPHALOPATHY AUTOIMMUNE EVAL, S
  • ENS2
  • ENCEPHALOPATHY AUTOIMMUNE EVAL, S
  • LAB10600

Procedure Name

ENCEPHALOPATHY AUTOIMMUNE EVAL, S

Procedure Master Number

LAB10600

Procedure ID

111704

Clinical Info

Mayo code ENS2
Evaluating new onset encephalopathy (noninfectious or metabolic) comprising confusional states, psychosis, delirium, memory loss, hallucinations, movement disorders, sensory or motor complaints, seizures, dyssomnias, ataxias, nausea, vomiting, inappropriate antidiuresis, coma, dysautonomias, or hypoventilation in serum specimens

The following accompaniments should increase of suspicion for autoimmune encephalopathy:
-Headache
-Autoimmune stigmata (personal or family history or signs of diabetes mellitus, thyroid disorder, vitiligo, poliosis [premature graying], myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus)
-History of cancer
-Smoking history (20+ pack years) or other cancer risk factors
-Inflammatory cerebral spinal fluid (or isolated protein elevation)
-Neuroimaging signs suggesting inflammation

Evaluating limbic encephalitis (noninfectious)

Directing a focused search for cancer

Investigating encephalopathy appearing in the course or wake of cancer therapy and not explainable by metastasis or drug effect

Specimen Sources

 Blood, Arterial Blood, Capillary Blood, Central Line Blood, Venous

Specimen Types

 Blood

Container

Red Top Tube

Collection Instructions

Container/Tube: Gold Top or Red Top Tube
Specimen: 4.0 mL serum (2.5 mL min)

Patient Preparation:
1. For optimal antibody detection, specimen collection is recommended prior to initiation of immunosuppressant medication or intravenous immunoglobulin treatment.
2. This test should not be requested in patients who have recently received radioisotopes, therapeutically or diagnostically, because of potential assay interference. The specific waiting period before specimen collection will depend on the isotope administered, the dose given, and the clearance rate in the individual patient. Specimens will be screened for radioactivity prior to analysis. Radioactive specimens received in the laboratory will be held 1 week and assayed if sufficiently decayed, or canceled if radioactivity remains.
3. Patient should have no general anesthetic or muscle-relaxant drugs in the previous 24 hours.

Specimen Volume

4.0 mL serum (2.5 mL min)

Transport Instructions

Refrigerated

Specimen Stability

72 Hours Room Temperature
28 Days Refrigerated or Frozen

Methodology

Indirect Immunofluorescence Assay (IFA)
Cell-Binding Assay (CBA)
Western Blot (WB)
Immunoblot (IB)
Radioimmunoassay (RIA)

Days Performed

TAT: 9-13 Days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

CPT

86255 x 23
86341
LOINC Code: 94697-0

PDM

 1759374

Only Orderable at Locations:

 Orderable Everywhere

Results
Component Name Base Name Common Name External Name
ENCEPHALOPATHY, INTERPRETATION, S ENCEPINTRPS ENCEP INTERP S Encephalopathy, Interpretation, S
IFA NOTES IFANOTES IFA NOTES IFA Notes
NEURONAL (V-G) K+ CHANNEL AB, S VGKCHANAB NEURONAL VOLTAGE GATED K CHANNEL AB Neuronal (V-G) K+ Channel Ab, S
AMPA-R ABCBA AMPARABCBA AMPA R ABCBA AMPA-R Ab CBA, S
AMPHIPHYSIN AB, S AMPHIPABS AMPHIP AB S Amphiphysin Ab, S
AGNA-1, S AGNA1S AGNA 1 S AGNA-1, S
ANNA-1, S ANNA1S ANNA 1 S ANNA-1, S
ANNA-2, S ANNA2S ANNA 2 S ANNA-2, S
ANNA-3, S ANNA3S ANNA 3 S ANNA-3, S
CASPR2-IGG CBA, S CASPR2IGCBAS CASPR2 IGG CBA S CASPR2-IgG CBA, S
REFLEX ADDED REFADD REFLEX ADDED Reflex Added
CRMP-5-IGG WESTERN BLOT CR5IGWESBLOT CR 5 IGG WES BLOT CRMP-5-IgG, S
DPPX AB CBA, S DPPXABCBAS DPPX AB CBA, S DPPX Ab CBA, S
GABA-B- RECEPTOR ANTIBODY BY CBA, SERUM GABABABCBA GABA B ABCBA GABA-B Ab CBA, S
GLUTAMIC ACID DECARBOXYLASE ANTIBODY GADAB GLUTAMIC ACID DECARB AB GAD65 Ab Assay, S
GLIAL FIBRILLARY ACIDIC PROTEIN.ALPHA SUBUNIT AB IGG GFAPIFA GLIAL FIBRILLARY ACIDIC PROTEIN ALPHA SUBUNIT AB IGG GFAP IFA, S
METABOTROPIC GLUTAMATE RECEPTOR 1 AB IGG MGLUR1ABIFA METABOTROPIC GLUTAMATE RECEPTOR 1 AB IGG mGluR1 Ab IFA, S
LGI1-IGG CBA, S LGI1IGGCBAS LGGI1 IGG CBA S LGI1-IgG CBA, S
NEUROCHONDRIN AB NEUROCHIFA NEUROCHONDRIN AB Neurochondrin IFA, S
DIPEPTIDYL AMINOPEPTIDASE-LIKE PROTEIN 6 AB IGG DPPXABIFA DIPEPTIDYL AMINOPEPTIDASE LIKE PROTEIN 6 AB IGG Dipeptidyl aminopeptidase-like protein 6 AB IGG
NMDA-R ABCBA NMDARABCBA NMDA R ABCBA NMDA-R Ab CBA, S
PCA-1, S PCA1S PCA 1 S PCA-1, S
PCA-2, S PCA2S PCA 2 S PCA-2, S
PCA-TR, S PCATRS PCA TR S PCA-Tr, S
NEUROCHONDRIN IFA, CSF NEURCHAB NEUROCHONDRIN IFA, CSF Neurochondrin IFA, CSF
PURKINJE CELL CYTOPLASMIC AB TYPE 2 PURCYTO2 PURKINJE CELL CYTOPLASMIC AB TYPE 2 PCA-2, CSF
PURKINJE CELL CYTOPLASMIC AB TYPE 1 PURCYTO1 PURKINJE CELL CYTOPLASMIC AB TYPE 1 PCA-1, CSF
NMDA-R AB CBA, CSF NMDARABCBA NMDA R AB CBA, CSF NMDA-R Ab CBA, CSF
NIF IFA, CSF NIFIFA NIF IFA, CSF NIF IFA, CSF
NMDAR- ABCBAC NMDARABCBAC NMDAR ABCBAC NMDA-R Ab CBA, S

Result Interpretation

See Report

Forms
edit